Trials / Completed
CompletedNCT00329186
Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects
A Randomized, Open-Label, Two-Period, Parallel Group, Crossover Study to Evaluate the Pharmacokinetics of Venlafaxine Extended-Release and DVS SR in Healthy Subjects Who Are Extensive or Poor Cytochrome P450 2D6 Substrate Metabolizers
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine if the relative difference in PK between extensive metabolizers (EMs) and poor metabolizers (PMs) is the same with desvenlafaxine SR and venlafaxine ER when a single dose is administered.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | desvenlafaxine SR | |
| DRUG | venlafaxine ER |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2007-06-01
- Completion
- 2007-06-01
- First posted
- 2006-05-24
- Last updated
- 2013-02-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00329186. Inclusion in this directory is not an endorsement.